Fisher & Paykel Healthcare (F&P) has upgraded its full year guidance again after gaining the right to sell its new full face mask in the United States.
One of the breathing masks built by F&P Healthcare to treat obstructive sleep apnoea. Photo: Supplied / Fisher and Paykel Healthcare
The company said the sale of the new full face mask used in the treatment of obstructive sleep apnoea (OSA) was expected to add $10 million to its previous guidance and $20m to sales.
F&P is now forecasting a net profit of between $255m to $265m for the year ended in March, with revenue of $1.19 billion.
The updated guidance also assumed a New Zealand dollar exchange rate of US$0.63, versus US$0.64 in the previous guidance, provided in August.
"We have had an ongoing strong start to the year in our hospital product group and our new OSA mask, Vitera, has been well received in Australia, Canada, New Zealand and Europe," said managing director Lewis Gradon.
"Clearance of Vitera for sale in the US this month is sooner than we had previously guided and this has been a meaningful contributor to the increase in our guidance."